Morgan Stanley Reiterates Overweight on Intra-Cellular Therapies, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $80.
July 11, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Intra-Cellular Therapies, maintaining a price target of $80.
The reiteration of an Overweight rating by a major financial institution like Morgan Stanley indicates a positive outlook for the company. The maintained price target of $80 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100